Skye Bioscience

SKYE

Market cap $32.7M

NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE).

LOS ANGELES, Jan. 14, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Skye Bioscience, Inc., (“Skye” or the “Company”) (NASDAQ: SKYE) investors of a class action on behalf of investors that bought securities between November 4, 2024 and October 3, 2025, inclusive (the “Class Period”). Skye investors have until January 16, 2026 to file a lead plaintiff motion.

Faruqi & Faruqi, LLP Securities Litigation Partner  James (Josh) Wilson Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options

NEW YORK, Jan. 14, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Skye Bioscience, Inc. ("Skye Bioscience, Inc." or the "Company") (NASDAQ: SKYE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Skye Bioscience, Inc. investors who were adversely affected by alleged securities fraud between November 4, 2024 and October 3, 2025.

PHILADELPHIA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”) on behalf of investors who purchased or otherwise acquired Skye securities during the period of November 4, 2024 through October 3, 2025 (the “Class Period”), inclusive.

LOS ANGELES, Jan. 14, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Skye Bioscience, Inc. ("Skye" or "the Company") (NASDAQ: SKYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of SKYE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

LOS ANGELES, Jan. 14, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Skye Bioscience, Inc. ("Skye" or "the Company") (NASDAQ: SKYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 4, 2024 and October 3, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before January 16, 2026.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Skye to Contact Him Directly to Discuss Their Options If you purchased or acquired securities in Skye between November 4, 2024 and October 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - January 13, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ: SKYE) and reminds investors of the January 16, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

PHILADELPHIA, Jan. 13, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Skye Bioscience, Inc. (NASDAQ: SKYE) ("Skye" or the "Company") on behalf of investors who purchased or otherwise acquired Skye securities during the period of November 4, 2024 through October 3, 2025 (the "Class Period"), inclusive. Investor Deadline: Investors who purchased Skye securities during the Class Period may, no later than January 16, 2026 , seek to be appointed as a lead plaintiff representative of the class.

LOS ANGELES, Jan. 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Skye Bioscience, Inc., (“Skye” or the "Company") (NASDAQ: SKYE) investors of a class action on behalf of investors that bought securities between November 4, 2024 and October 3, 2025, inclusive (the “Class Period”). Skye investors have until January 16, 2026 to file a lead plaintiff motion.